|
|
Strategic Navigators

Multiple Sclerosis Competitive Landscape

Pages: 121
Published: October 2022
Individual License: $4,950
Team License: $4,950
multiple sclerosis treatment, multiple sclerosis competitor analysis, multiple sclerosis competitive intelligence, multiple sclerosis market research

Multiple Sclerosis Competitive Landscape depicts the current state of the market and how each existing multiple sclerosis treatment shapes the environment for pipeline MS drugs. Vivisum Partners developed this guide to provide commercial teams insights on how neurologists evaluate the clinical benefits of each multiple sclerosis treatment, as well as each treatment’s target patient characteristics. Finally, the report includes data on pipeline familiarity and expectations for how each developing drug will compete in the multiple sclerosis market.

As the multiple sclerosis market evolves, the brands that neurologists most rely upon may gain or lose favor depending on changes in the overall competitive landscape. The strategies that competing MS brands implement may alter how HCPs think about an individual multiple sclerosis treatment. Understanding the insights contained in this guide will help commercial executives develop more robust strategies for their multiple sclerosis brands.

Lastly, To navigate the many challenging aspects of the current multiple sclerosis market, brand teams need to fully grasp how new market entrants will impact existing brands. The data in Multiple Sclerosis Competitive Landscape show how individual pipeline drugs will compete against existing brands, which brands will face the biggest competition and which developing drugs have the best chance to find success.

Overview of the Multiple Sclerosis Treatment Competitive Landscape

The multiple sclerosis market has more than a dozen viable options that neurologists evaluate when treating patients. Multiple Sclerosis Competitive Landscape is a robust examination of current multiple sclerosis market dynamics. The strategy guide analyzes neurologists’ expectations for the multiple sclerosis market’s major and minor brands. It also identifies which multiple sclerosis treatment currently moving through the development pipeline has the best chance of impacting the market.

This report focuses on the multiple sclerosis market and its

  • Current market positions
  • Branded drugs
  • Competitors and expectations
  • Pipeline products
  • Patient share per product
  • Expected usage in the next year
  • Prescription patterns

The report covers the following top brands in the multiple sclerosis market:

  • Aubagio
  • Bafiertam
  • Gilenya
  • Kesimpta
  • Lemtrada
  • Mavenclad
  • Mayzent
  • Ocrevus
  • Ponvory
  • Tysabri
  • Tecfidera
  • Vumerity
  • Zeposia

The report also includes analysis of the following multiple sclerosis pipeline drugs:

  • Bee venom
  • Evobrutinib
  • Divozilimab
  • Naltrexone
  • Orelabrutinib
  • Tolebrutinib
  • Vidofludimus

Strategic Questions Answered about the Multiple Sclerosis Treatment Competitive Landscape

  • Market Positions: Which multiple sclerosis drugs are Rising Leaders, Established Leaders, Falling Leaders, Rising Challengers, Stable Laggards and Outsiders?
  • Competitive Landscape: How are MS brands competitively positioned? Who are the top 2 – 3 competitors for each of the top brands within the multiple sclerosis treatment landscape?
  • Prescription Trends: Which brands do physicians expect to prescribe more vs. less over the next 12-months?
  • Pipeline Impact: Which multiple sclerosis treatment will be most impacted in the future by treatments currently in development?

Summary of Strategic Insights about the Multiple Sclerosis Competitive Landscape

  • Neuros expect Kesimpta to see the most significant growth in prescription volume compared to competitors. Access concerns have limited its patient share compared to its competitors.
  • While Ocrevus has the highest patient share, it is not by a large margin. Compared to other disease states, patient share is somewhat evenly distributed among options, again pointing to a competitive landscape.
  • Out of the pipeline therapies, Evobrutinib has the most familiarity, with most HCPs being familiar. It is expected to compete most with escalation therapies and be superior on tolerability.

Benefits of Purchasing Multiple Sclerosis Competitive Landscape

  • Cost-efficient insights about companies and brands in the multiple sclerosis market to support your strategic marketing decisions.
  • Insights drawn from in-depth interviews among US KOLs and surveys of more than 125 neurologists
  • A complimentary 30-minute workshop with you (and your team)
  • Unlimited support from Vivisum’s multiple sclerosis strategist for 1-year

Table of Contents

Executive Summary – 6
Research Methodology: Robust Insights from US Neurologists – 7
The Strategic Six: Key Insights about the MS Competitive Landscape – 8
Multiple Sclerosis Treatment Usage Summary – 9
MS Market Summary – 10
Competitors: Current Products – 11
Competitors: Pipeline Products – 12

MS Competitive Landscape – 13
  • Patient Share per Product – 14
  • Increased Usage Expected in the Next Year – 15
  • Decreased Usage Expected in the Next Year – 16
  • Stable Rx Patterns – 17
MS Competitor Brand Profiles – 18
    Ocrevus Top Brand Competitors – 19
    • Ocrevus Top Competitors – 20
    • Ocrevus Brand Competitor Prescribing Patterns – 21
    • Ocrevus Brand Competitor Rational Perceptions – 22
    • Ocrevus Competitor Emotional Brand Personalities – 23
    • Ocrevus Brand Competitor Prescribing Patterns – 24
    Tecfidera Top Brand Competitors – 25
    • Tecfidera Top Competitors – 26
    • Tecfidera Brand Competitor Prescribing Patterns – 27
    • Tecfidera Brand Competitor Rational Perceptions – 28
    • Tecfidera Competitor Emotional Brand Personalities – 29
    • Tecfidera Brand Competitor Prescribing Patterns – 30
    Tysabri Top Brand Competitors – 31
    • Tysabri Top Competitors – 32
    • Tysabri Brand Competitor Prescribing Patterns – 33
    • Tysabri Brand Competitor Rational Perceptions – 34
    • Tysabri Competitor Emotional Brand Personalities – 35
    • Tysabri Brand Competitor Prescribing Patterns – 36
    Gilenya Top Brand Competitors – 37
    • Gilenya Top Competitors – 38
    • Gilenya Brand Competitor Prescribing Patterns – 39
    • Gilenya Brand Competitor Rational Perceptions – 40
    • Gilenya Competitor Emotional Brand Personalities – 41
    • Gilenya Brand Competitor Prescribing Patterns – 42
    Aubagio Top Brand Competitors – 43
    • Aubagio Top Competitors – 44
    • Aubagio Brand Competitor Prescribing Patterns – 45
    • Aubagio Brand Competitor Rational Perceptions – 46
    • Aubagio Competitor Emotional Brand Personalities – 47
    • Aubagio Brand Competitor Prescribing Patterns – 48
    Lemtrada Top Brand Competitors – 49
    • Lemtrada Top Competitors – 50
    • Lemtrada Brand Competitor Prescribing Patterns – 51
    • Lemtrada Brand Competitor Rational Perceptions – 52
    • Lemtrada Competitor Emotional Brand Personalities – 53
    • Lemtrada Brand Competitor Prescribing Patterns – 54
    Kesimpta Top Brand Competitors – 55
    • Kesimpta Top Competitors – 56
    • Kesimpta Brand Competitor Prescribing Patterns – 57
    • Kesimpta Brand Competitor Rational Perceptions – 58
    • Kesimpta Competitor Emotional Brand Personalities – 59
    • Kesimpta Brand Competitor Prescribing Patterns – 60
    Zeposia Top Brand Competitors – 61
    • Zeposia Top Competitors – 62
    • Zeposia Brand Competitor Prescribing Patterns – 63
    • Zeposia Brand Competitor Rational Perceptions – 64
    • Zeposia Competitor Emotional Brand Personalities – 65
    • Zeposia Brand Competitor Prescribing Patterns – 66
    Mayzent Top Brand Competitors – 67
    • Mayzent Top Competitors – 68
    • Mayzent Brand Competitor Prescribing Patterns – 69
    • Mayzent Brand Competitor Rational Perceptions – 70
    • Mayzent Competitor Emotional Brand Personalities – 71
    • Mayzent Brand Competitor Prescribing Patterns – 72
    Vumerity Top Brand Competitors – 73
    • Vumerity Top Competitors – 74
    • Vumerity Brand Competitor Prescribing Patterns – 75
    • Vumerity Brand Competitor Rational Perceptions – 76
    • Vumerity Competitor Emotional Brand Personalities – 77
    • Vumerity Brand Competitor Prescribing Patterns – 78
    Ponvory Top Brand Competitors – 79
    • Ponvory Top Competitors – 80
    • Ponvory Brand Competitor Prescribing Patterns – 81
    • Ponvory Brand Competitor Rational Perceptions – 82
    • Ponvory Competitor Emotional Brand Personalities – 83
    • Ponvory Brand Competitor Prescribing Patterns – 84
    Mavenclad Top Brand Competitors – 85
    • Mavenclad Top Competitors – 86
    • Mavenclad Brand Competitor Prescribing Patterns – 87
    • Mavenclad Brand Competitor Rational Perceptions – 88
    • Mavenclad Competitor Emotional Brand Personalities – 89
    • Mavenclad Brand Competitor Prescribing Patterns – 90
    Bafiertam Top Brand Competitors – 91
    • Bafiertam Top Competitors – 92
    • Bafiertam Brand Competitor Prescribing Patterns – 93
    • Bafiertam Brand Competitor Rational Perceptions – 94
    • Bafiertam Competitor Emotional Brand Personalities – 95
    • Bafiertam Brand Competitor Prescribing Patterns – 96
Pipeline Competitors – 97
    Pipeline Product Familiarity – 98
    • Evobrutinib Competitors and Expectations – 99
    • Evobrutinib Top Competitors – 100
    • Evobrutinib Expectations – 101
    • Tolebrutinib Competitors and Expectations – 102
    • Tolebrutinib Top Competitors – 103
    • Tolebrutinib Expectations – 104
    • Orelabrutinib Competitors and Expectations – 105
    • Orelabrutinib Top Competitors – 106
    • Orelabrutinib Expectations – 107
    • Divozilimab Competitors and Expectations – 108
    • Divozilimab Top Competitors – 109
    • Divozilimab Expectations – 110
    • Vidofludimus Competitors and Expectations – 111
    • Vidofludimus Top Competitors – 112
    • Vidofludimus Expectations – 113
    • Bee Venom Competitors and Expectations – 114
    • Bee Venom Expectations – 116
    • Naltrexone Hydrochloride Competitors and Expectations – 117
    • Naltrexone Hydrochloride Top Competitors – 118
    • Naltrexone Hydrochloride Expectations – 119

Contact – 120

Complete the form below for a sample of this research.

Name
Newsletter signup